Download PDF
Pneumologie 2006; 60(11): 694-700
DOI: 10.1055/s-2006-944278
Serie: Pharmakologische Therapie (2)
© Georg Thieme Verlag Stuttgart · New York

Pharmakotherapie bei Schwerem Akutem Respiratorischem Syndrom (SARS)

Pharmacotherapy of Severe Acute Respiratory Syndrome (SARS)L.  von Hagen1 , M.  W.  Pletz1 , N.  Dickgreber1 , H.  Golpon1 , T.  T.  Bauer2 , P.  Zabel3 , T.  Welte1 , D.  A.  Groneberg1
  • 1Abteilung Pneumologie, Zentrum Innere Medizin, Medizinische Hochschule Hannover (Direktor: Univ.-Prof. Dr. T. Welte)
  • 2Zentrum für Pneumologie und Thoraxchirurgie Heckeshorn, Klinik für Pneumologie, HELIOS Emil-von-Behring, Berlin (Chefarzt: PD Dr. T. T. Bauer)
  • 3Forschungszentrum Borstel, Medizinische Klinik, Borstel (Direktor: Univ.-Prof. Dr. P. Zabel)
  • 4Medizinische Klinik III, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Universität zu Lübeck (Direktor: Univ.-Prof. Dr. P. Zabel)
Further Information

Publication History

eingereicht 10. 7. 2006

akzeptiert 26. 7. 2006

Publication Date:
16 November 2006 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Das schwere akute respiratorische Syndrom (SARS) ist die erste bedeutende neue Infektionskrankheit dieses Jahrtausends und wird durch das SARS-Coronavirus (SARS-CoV) hervorgerufen. SARS geht mit einer erheblichen Morbidität und Mortalität einher und trat erstmals als Epidemie von 2002 - 2003 auf. Bis heute ist noch kein spezifisch wirksames Therapeutikum gegen das SARS-Coronavirus gefunden worden. Aufgrund des schnellen Voranschreitens der Epidemie 2002 - 2003 war es nicht möglich, multizentrierte, kontrollierte, randomisierte Studien durchzuführen. Daher existieren noch keine allgemeingültigen therapeutischen Richtlinien für diese neue Viruserkrankung. Seit dem Ausbruch von SARS untersuchen Wissenschaftler potenziell wirksame Substanzen gegen das Virus hauptsächlich mittels In-vitro-Tests und an Tiermodellen. Die vorliegende Arbeit analysiert die derzeit zur Pharmakotherapie vorhandenen In-vitro- und In-vivo-Ergebnisse.

Abstract

Severe acute respiratory syndrome (SARS) constitutes the first new infectious disease of the current millennium. It is caused by the novel SARS-Coronavirus (SARS-CoV). SARS is related to a high morbidity and mortality and first appeared during an epidemic in 2002 - 2003. To date no specific therapy against the SARS-CoV is available. Due to the rapid spread of SARS during the epidemics in 2002 - 2003, randomised and controlled multicentre studies were not performed. Therefore, general guidelines have not been developed. Since the outbreak, scientists have been testing potential antiviral substances using in vitro and animal models. This study analyses the presently available in vitro and in vivo data on the pharmacotherapy of SARS.

Literatur

  • 1 Groneberg D A, Poutanen S M, Low D E. et al . Treatment and vaccines for severe acute respiratory syndrome (SARS).  Lancet Infect Dis. 2005;  5 147-155
    PubMedGoogle Scholar
  • 2 Poon L L, Guan Y, Nicholls Y M. et al . The aetiology, origins and diagnosis of severe acute respiratory syndrome.  Lancet Infect dis. 2004;  4 663-671
    PubMedGoogle Scholar
  • 3 Reilley B, Herp M van, Sermand D. et al . SARS and Carlo Urbani.  N Engl J Med. 2003;  348 1951-1952
    CrossrefPubMedGoogle Scholar
  • 4 World Health Organization (WHO) .Summary of propable SARS cases with onset of illness from 1. November 2002 to 31. July 2003. http//www.who.int/csr/sars/country/table2004_04_21/en 2003 (accessed feb 3, 2005)
    Google Scholar
  • 5 World Health Organization Multicentre Collaborative Network for Severe Acute Respiratory Syndrome Diagnosis . A multicentre collaboration to investigate the cause of severe acute respiratory syndrome.  Lancet. 2003;  361 1730-1733
    CrossrefPubMedGoogle Scholar
  • 6 Peiris J S, Lai S T, Poon L L. Coronavirus as a possible cause of severe acute respiratory syndrome.  Lancet. 2003;  361 1319-1325
    CrossrefPubMedGoogle Scholar
  • 7 Drosten C, Gunter S, Preiser W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome.  N Engl J Med. 2003;  348 1967-1976
    CrossrefPubMedGoogle Scholar
  • 8 Ksiazek T G, Erdmann D, Goldsmith C S. A novel coronavirus associated with severe acute respiratory syndrome.  N Engl J Med. 2003;  348 1953-1966
    CrossrefPubMedGoogle Scholar
  • 9 Zhang Q F, Cui J M, Huang X J. Morpholigy and morphogenesis of severe acute respiratory syndrome (SARS)-associated virus.  Chin J Biochem Biophys. 2003;  35 587-591
    PubMedGoogle Scholar
  • 10 Cavanagh D. Nidovirales: a new order comprising Coronaviridae and Arteriviridae.  Arch Virol. 1997;  142 629-633
    PubMedGoogle Scholar
  • 11 Sidell S, Wege H, ter Meulen V. The structure and replication of coronaviruses.  Curr Top Microbiol Immunol. 1982;  99 131-163
    PubMedGoogle Scholar
  • 12 Wege H, Sidell S, ter Meulen V. The biology and pathogenesis of Coronaviruses.  Curr Top Microbiol Immunol. 1982;  99 165-200
    PubMedGoogle Scholar
  • 13 Guan Y, Zheng B J, He Y Q. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.  Science. 2003;  302 276-278
    CrossrefPubMedGoogle Scholar
  • 14 Bonn D. Wild animals could be source of SARS.  Lancet Infect Dis. 2003;  3 395
    PubMedGoogle Scholar
  • 15 Chan P KS, Tang J W. SARS: clinical presentation, transmission, pathogenesis and treatment options.  Clinical Science. 2006;  110 193-204
    CrossrefPubMedGoogle Scholar
  • 16 Dietel M, Suttorp N, Zeitz M. Harrisons Innere Medizin, 16. Aufl. ABW-Wissenschaftsverlag 2005
    Google Scholar
  • 17 Marra M A, Jones S J, Astell C R. The genome sequence of the SARS-associated coronavirus.  Science. 2003;  300 1399-1404
    CrossrefPubMedGoogle Scholar
  • 18 Groneberg D A, Hilgenfeld R, Zabel P. Molecular mechanisms of severe acute respiratory syndrome (SARS).  Respir Res. 2005;  6 8
    CrossrefPubMedGoogle Scholar
  • 19 Lai M M, Cavanagh D. The molecular biology of coronaviruses.  Adv Virus Res. 1997;  48 1-100
    PubMedGoogle Scholar
  • 20 Wentworth D E, Gillim-Ross L, Espina N. et al . Mice susceptible to SARS coronavirus.  Emerge Infect Dis. 2004;  10 1293-1296
    PubMedGoogle Scholar
  • 21 Martina B E, Haagmans B L, Kuikan T. Virology: SARS virus infection of cats and ferrets.  Nature. 2003;  425 915
    PubMedGoogle Scholar
  • 22 Tsui P T, Kwok M L, Yuen H. et al . Sevre acute respiratory syndrome: clinical outcome and prognostic correlates.  Emerg Infect Dis. 2003;  9 1064-1069
    PubMedGoogle Scholar
  • 23 Donnelly C A, Ghani A C, Leung G M. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong.  Lancet. 2003;  361 1761-1766
    CrossrefPubMedGoogle Scholar
  • 24 Bitnun A, Allen U, Heurter H. Children hospitalized with severe acute respiratory syndrome - related illness in Toronto.  Pediatrics. 2003;  112 e261
    CrossrefPubMedGoogle Scholar
  • 25 Zhaori G. Antiviral treatment of SARS: Can we draw any conclusions?.  CMAJ. 2003;  169 1165-1166
    PubMedGoogle Scholar
  • 26 Hof H, Müller R L, Dörris R. Mikrobiologie-Duale Reihe. 1. Aufl. Stuttgart/D 2000
    Google Scholar
  • 27 Crotty S, Maag D, Arnold J J. The broad-Spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen.  Nat Med. 2000;  6 1375-1379
    PubMedGoogle Scholar
  • 28 Zhang K W, Ho P L, Ooi G C. A cluster of cases of severe acute respiratory syndrome in Hong Kong.  N Engl J Med. 2003;  348 1977-1985
    CrossrefPubMedGoogle Scholar
  • 29 Lee N, Hui D, Wu A. A major outbreak of severe acute respiratory syndrome in Hong Kong.  N Engl J Med. 2003;  348 1986-1994
    CrossrefPubMedGoogle Scholar
  • 30 Peiris J S, Chu C M, Cheng V C. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.  Lancet. 2003;  361 1767-1772
    CrossrefPubMedGoogle Scholar
  • 31 Zhao Z, Zhang F, Xu M. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China.  J Med Microbiol. 2003;  52 715-720
    CrossrefPubMedGoogle Scholar
  • 32 Stroher U, DiCaro A, Li Y. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alfa.  J Infect Dis. 2004;  189 1164-1176
    CrossrefPubMedGoogle Scholar
  • 33 Cinatl J, Morgenstern B, Bauer G. et al . Glycyrrhizin, an active component of liquorrice roots, and replication of SARS-associated coronavirus.  Lancet. 2003;  361 2045-2046
    CrossrefPubMedGoogle Scholar
  • 34 Mazzulli T, Farcas G A, Poutanan S M. Sevre acute respiratory syndrome-associated corornavirus in lung tissue.  Emerge Infect Dis. 2004;  10 20-24
    PubMedGoogle Scholar
  • 35 Knowles S R, Phillips E J, Dresser L. et al . Common adverse events associated with the use of Ribavirin for severe acute respiratory syndrome in Canada.  Clin Infect Dis. 2003;  37 1139-1142
    CrossrefPubMedGoogle Scholar
  • 36 Zhu C M, Cheng V C, Hung I F. Role of Lopinavir/Ritonavir in the treatment of SARS: Initial virological and clinical findings.  Thorax. 20 004;  59 252-256
    PubMedGoogle Scholar
  • 37 Chan K S, Lai S T, Chu C M. M. Treatment of SARS with Lopinavir/Ritonavir: A multicentre retrospective matched cohort study.  Hong Kong Med J. 2003;  9 399-406
    PubMedGoogle Scholar
  • 38 Yamamoto N, Yang R, Joshinaka Y. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.  Biochem Biophys Res Commun. 2004;  318 719-725
    CrossrefPubMedGoogle Scholar
  • 39 Barnard D L, Hubbart V D, Burten J. Inhibition of SARS-associated coronavirus (SARSCoV) by calpain inhibitors in beta-D-N4-hydroxycytidine.  Antivir Chem Chemother. 2004;  15 15-22
    PubMedGoogle Scholar
  • 40 Li W, Moore M J, Vasilieva N. Angiotensin-converting enzyme is a functional reseptor for the SARS coronavirus.  Nature. 2003;  426 450-454
    Google Scholar
  • 41 Huang L, Sexton D J, Skogerson K. novel peptide inhibitors of angiotensin-converting enzyme2.  J Biol Chem. 2003;  278 15 532-15 540
    PubMedGoogle Scholar
  • 42 Dales N A, Gould A E, Brown J A. Substrate based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors.  J Am Chem Soc. 2002;  124 11 852-11 853
    PubMedGoogle Scholar
  • 43 Sui J, Li W, Murakami A. Potent neutralisation of SARS coronavirus by a human mAb to S1 protein that blocks reseptor association.  Prog Natl Acad Sci USA. 2004;  101 2536-2541
    PubMedGoogle Scholar
  • 44 Liu S, Xiao G, Chen Y. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.  Lancet. 2004;  363 938-947
    CrossrefPubMedGoogle Scholar
  • 45 Kliger Y, Levanon E Y. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.  BMC Microbiol. 2003;  3 20
    CrossrefPubMedGoogle Scholar
  • 46 Zhang R, Guo Z, Lu J. Inhibiting SARS-associated coronavirus by small interfering RNA.  Chin Med J. 2003;  116 1262-1264
    PubMedGoogle Scholar
  • 47 Jacque J M, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference.  Nature. 2002;  418 435-438
    PubMedGoogle Scholar
  • 48 Kabadia S B, Brideau-Anderson A, Chisari F V. Interference of hepatitis C virus RNA replication by short interfering RNAs.  Proc Natl Acad Sci USA. 2003;  100 2014-2018
    CrossrefPubMedGoogle Scholar
  • 49 Hamasaki K, Nakao K, Mazumoto K. et al . Short interfering RNA-directed inhibition of hepatitis B virus replication.  FEBS Lett. 2003;  543 51-54
    CrossrefPubMedGoogle Scholar
  • 50 Zhang J, Li T, Fu L. Silencing SARS-CoV spike protein expression in cultured cells by RNA interference.  FEBS Lett. 2004;  560 141-146
    CrossrefPubMedGoogle Scholar
  • 51 He M L, Zheng B, Peng Y. Inhibition of SARS-associated coronavirus infection and replication by RNA interference.  JAMA. 2003;  290 2665-2666
    CrossrefPubMedGoogle Scholar
  • 52 Sasaki H, Takai M, Kobajashi M. et al . Effect of Glycyrrhizin, an activ component of liquorrice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients.  Pathobiology. 2002;  70 229-236
    CrossrefPubMedGoogle Scholar
  • 53 Kumada H. Lon-term treatment of chronic hepatitis C with Glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.  Oncology. 2002;  62 (suppl 1) 94-100
    PubMedGoogle Scholar
  • 54 Matsuo K, Takenaka K, Chimomura H. Lamivudine and Glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-hodgkin lymphoma.  Leuk Lymphoma. 2001;  41 191-195
    PubMedGoogle Scholar
  • 55 Kim J y, Choi C Y, Lee K J. Induction of inducible nitric oxide synthase and proinflammatory cyrokines expression by o, p'-DDT in macrophages.  Toxicol Lett. 2004;  147 261-269
    CrossrefPubMedGoogle Scholar
  • 56 Keyaerts E, Vijgen L, Maes P. et al .Inhibition of SARS-CoV infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxid donor compound. 11th International Congress on Infectious Diseases. Cancun, Mexico March 4 - 7, 2004
    Google Scholar
  • 57 Wu C J, Jan J T, Chen C M. Inhibition of SARS coronavirus replicaton by niclosamide.  Antimicrob Agents Chemother. 2004;  48 2693-2696
    CrossrefPubMedGoogle Scholar
  • 58 Gomersall T D, Kargel M J, Lapinski S E. Pro/Con clinical debate: steroids are a key component in the teratment of SARS.  Crit Care. 2004;  8 105-107
    CrossrefPubMedGoogle Scholar
  • 59 Nicholls J M, Poon L L, Lee K C. Lung pathology of fatal SARS.  Lancet. 2003;  361 1773-1778
    CrossrefPubMedGoogle Scholar
  • 60 Booth T M, Matukas L M, Tomlinson G A. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.  JAMA. 2003;  289 2801-2809
    CrossrefPubMedGoogle Scholar
  • 61 Hsu L Y, Lee C G, Green J A. SARS in Singapore: clinical features of index patient and initial contacts.  Emerg Infect Dis. 2003;  9 713-717
    CrossrefPubMedGoogle Scholar
  • 62 Ho J C, Ooi G C, Mok T Y. High-dose pulse versus nonpulse corticosteroid regiments in SARS.  Am J Respir Crit Cer Med. 2003;  168 1449-1456
    PubMedGoogle Scholar
  • 63 Wang H, Ding Y, Li X. et al . Fatal aspergillosis in a patient with SARS who was treated with corticosteroids.  N Engl J Med. 2003;  349 507-508
    CrossrefPubMedGoogle Scholar
  • 64 Chan K S, Zheng J P, Mok Y W. SARS: prognosis, outcome and sequelae.  Respirology. 2003;  8 (suppl) S36-40
    CrossrefPubMedGoogle Scholar
  • 65 Hong N, Du X K. Avascular necrosis of bone in SARS.  Clin Radiol. 2004;  59 602-608
    CrossrefPubMedGoogle Scholar
  • 66 Cinatl J R, Michaelis M, Scholz M. et al . Role of interference in the treatment of SARS.  Expert Opin Biol Ther. 2004;  4 827-836
    CrossrefPubMedGoogle Scholar
  • 67 Tan E L, Ooi E E, Lin C Y. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.  Emerg Infect Dis. 2004;  10 581-586
    PubMedGoogle Scholar
  • 68 Hensley L E, Fritz L E, Jahraling P B. et al . Interferon-β 1a and SARS coronavirus replication.  Emerg Infect Dis. 2004;  10 317-319
    PubMedGoogle Scholar
  • 69 Loutfy M R, Blatt L M, Siminovich K A. Intereferon alfacon-1 plus corticosteroids in SARS: a preliminary study.  JAMA. 2003;  290 3222-3228
    CrossrefPubMedGoogle Scholar
  • 70 Haagmanns B L, Kuiken T, Martina B E. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.  Nat Med. 2004;  10 290-293
    CrossrefPubMedGoogle Scholar
  • 71 Muller M P, McGeer A, Straus S E. et al . Clinical trials and novel pathogens: lessons learned from SARS.  Emerg Infect Dis. 2004;  10 389-394
    PubMedGoogle Scholar

Univ.-Prof. Dr. med. David Groneberg

Zentrum Innere Medizin, Abteilung Pneumologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1 OE6870

30625 Hannover

Email: groneberg.david@mh-hannover.de

      >